CureVac gets vaccine production support from Novartis

Health News
FILE PHOTO: A sign marks Novartis’ Institutes for Biomedical Research in Cambridge, Massachusetts, U.S., January 2, 2020. Picture taken January 2, 2020. REUTERS/Brian Snyder

FRANKFURT (Reuters) – German biotech firm CureVac has enlisted Swiss pharma giant Novartis to help with the production of its experimental COVID-19 vaccine.

Novartis plans to manufacture the mRNA molecules that the two-shot vaccine is based on as well as “bulk drug product” for up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022, the two companies said in statements on Thursday.

Delivery from the manufacturing site in Kundl, Austria, is expected to start in summer 2021, they added.

Source: Read Full Article

Related posts:

J&J applies for COVID-19 vaccine emergency authorisation from South Africa Novavax completes enrolling 30,000 people in U.S. trial of COVID-19 vaccine US records 1,225 coronavirus deaths in 24 hours: Johns Hopkins Europe's oldest person, 117-year-old French nun, survives COVID-19 Overflowing Czech hospitals seek patient transfers as 'UK variant' rages
, , , , , , , ,